Related Experiment Video
Updated: Aug 16, 2026
A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage
Published on: April 28, 2022
Encapsulating peritoneal sclerosis in paediatric peritoneal dialysis patients
Mesiha Ekim1, Suat Fitöz, Aydin Yagmurlu
1Department of Paediatric Nephrology, School of Medicine, Ankara University, Ankara, Turkey. ekim@medicine.ankara.edu.tr
Insights
Encapsulating peritoneal sclerosis (EPS) is a rare complication of chronic peritoneal dialysis (CPD) in children. This study found an incidence of 1.9% in paediatric patients, highlighting the need for radiological evaluation in cases of ultrafiltration failure.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Gastroenterology
Background:
- Encapsulating peritoneal sclerosis (EPS) is a severe complication of chronic peritoneal dialysis (CPD).
- Limited data exists on EPS in pediatric CPD patients, with most reports from Japan.
- This study aimed to determine the incidence and characteristics of EPS in a pediatric CPD cohort.
Observation:
- Two out of 104 pediatric patients (1.9%) were diagnosed with EPS.
- Patients had dialysis durations of 45 and 53 months with 6 and 8 peritonitis episodes.
- EPS symptoms appeared 7-14 days post-catheter removal, leading to CPD cessation and transition to hemodialysis due to persistent peritonitis.
Findings:
- One patient managed surgically experienced short-term recovery before mortality.
- Another patient treated with prednisolone showed sustained improvement at 16 months.
- EPS is a rare but significant complication of pediatric CPD.
Implications:
- Pediatric CPD patients presenting with ultrafiltration failure should undergo radiological assessment for EPS.
- Tailored management strategies are crucial for individual pediatric EPS cases.
- Further research is needed to understand and prevent EPS in pediatric populations.
Abstract:
Encapsulating peritoneal sclerosis (EPS) is a serious complication of chronic peritoneal dialysis (CPD). In contrast to the adult population, there are few studies regarding EPS in paediatric CPD patients, and the majority of reported patients are from Japan. The aim of the present report is to define the incidence of EPS in our paediatric CPD patients and to describe the clinical and laboratory characteristics. A total of 104 paediatric patients were followed from November 1989 to November 2003 and two were diagnosed as EPS (1.9%). The dialysis periods of these patients were 45 and 53 months with 6 and 8 peritonitis episodes, respectively. Clinical signs of EPS developed 7 and 14 days after the removal of the dialysis catheter, and CPD was replaced by haemodialysis because of persistent peritonitis. One patient was well after surgical management but died 6 months later. The second patient who was treated with prednisolone remained well at 16 months. In conclusion, EPS is a rare but important complication of CPD. We recommend that all patients on CPD who develop ultrafiltration failure be evaluated radiologically for the occurrence of EPS. Management should be tailored to the individual patient.
Related Concept Videos
01:30Peritoneal Dialysis I: Introduction and Procedure
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications